Angiodynamics (ANGO) Research & Development (2010 - 2026)

Angiodynamics has reported Research & Development for 17 years, with the latest figure at $7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 2.47% year-over-year to $7.1 million; the trailing twelve-month figure through Feb 2026 stood at $27.9 million (up 5.7% YoY), and the FY2025 full-year result was $26.2 million, down 16.79% from the prior year.
• Research & Development for Q1 2026 stood at $7.1 million, down from $7.8 million in the prior quarter.
• The five-year high for Research & Development was $8.7 million in Q4 2023, with the low at $6.3 million in Q3 2024.
• Historically, Research & Development has averaged $7.3 million across 5 years, with a median of $7.1 million in 2026.
• Annual changes were most pronounced in 2023 — Research & Development advanced 26.62% — and 2024, when it declined 25.69%.
• Angiodynamics' Research & Development stood at $6.8 million in 2022, then gained by 26.62% to $8.7 million in 2023, then decreased by 25.69% to $6.4 million in 2024, then gained by 20.73% to $7.8 million in 2025, then decreased by 8.81% to $7.1 million in 2026.
• The last three Research & Development figures came in at $7.1 million (Q1 2026), $7.8 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.